For survodutide storage and stability, there is no assigned expiry: it is an investigational acylated peptide with no approved label. Keep the sealed lyophilized powder cold, dark and dry; water drives most degradation. Let a cold vial reach room temperature before opening it, because condensation is the most common unrecorded loss.
- Survodutide has no approved product or labeled expiry anywhere, so storage figures quoted from approved incretin medicines do not apply to a research powder.
- Moisture, not freezer set point, is the dominant degradation driver for a lyophilized peptide.
- Letting a sealed vial reach room temperature before opening prevents condensation uptake, the most common unrecorded handling loss.
- The fatty acid chain that extends circulating half-life also makes the molecule interface-active and prone to adsorption at low concentrations.
- Glucagon-family backbones have a documented fibrillation tendency, so soluble aggregates need a size-exclusion or light-scattering method to detect.
- Each cold opening of a vial admits condensation, and the loss compounds across sessions without any visible sign.
Why is there no approved label to borrow from?
Survodutide, indexed in the development literature as BI 456906, is an investigational compound. As of the verification date on this page no approved product containing it exists anywhere, which means there is no package insert, no assigned expiry, and no published stability study a laboratory can point to for a research-grade powder. What circulates in its place are figures lifted from the labeling of approved incretin medicines: refrigerate at 2 to 8 °C, protect from light, discard after twenty-eight days in use.
Those numbers describe sterile aqueous formulations with excipients and a preservative system, filled and released under pharmaceutical quality systems, with a shelf life derived from stability work on that exact composition. They describe a different physical state and a different supply chain. Nothing in them applies to a lyophilized cake sitting in a research vial.
So storage decisions here rest on two things only: general peptide chemistry, and whatever the supplier's certificate documents for the specific lot in hand. That is a weaker footing than working from a licensed product, and it should be recorded as such. A confident month count assigned to a research powder without a stability study behind it is a convention someone repeated, not a measurement.
ICH Q1A(R2) is worth reading once for exactly this reason. It sets out what generating a shelf life actually involves: defined conditions, defined containers, real time points on real lots. Anything short of that produces an estimate, and estimates belong in the record labeled as estimates.
- Moisture — the dominant driver, and condensation delivers it
- Temperature — a rate modifier, not a mechanism
- Oxygen and light — oxidation of susceptible residues
- Interfaces and agitation — aggregation of a lipidated, glucagon-family backbone
- Cold openings: condensation each time, and the loss compounds
- The record — the only stability document an unapproved compound has
What does the structure imply for the bench?
Survodutide is described in the primary literature as a dual agonist at the glucagon receptor and the GLP-1 receptor. The publicly reported structure is a peptide of the glucagon family carrying α-aminoisobutyric acid substitutions and a fatty acid chain conjugated through a hydrophilic linker to a lysine side chain. Positional details vary in how different secondary sources report them; check the sequence against the certificate for your lot rather than against a summary page.
Two structural features matter for handling. The acylation is there to promote albumin binding and extend circulating half-life. On a bench, that same chemistry makes the molecule amphiphilic, and amphiphilic peptides concentrate at interfaces. The air-water boundary in a half-filled vial is a genuine site of loss, and adsorption to glass and to some plastics is a plausible route for material to go missing at low concentrations. That kind of loss shows up as a weak result rather than as anything visible.
The second feature is the backbone family. Glucagon itself is a 29-residue peptide with awkward solubility behavior around neutral pH and a well-documented tendency to form fibrils in solution. An engineered analog is not the parent peptide and Aib substitutions change the conformational picture, so do not assume identical aggregation kinetics. Do assume that aggregation is a live risk worth designing against, because the parent scaffold earned that reputation honestly.
The Aib residues resist enzymatic cleavage. They do nothing about hydrolysis, oxidation or interface-driven aggregation. Treating peptidase resistance as general stability is a common and expensive confusion.
Which degradation routes matter, and what controls each?
Peptides fail along a small, well-catalogd set of routes. Butreddy and colleagues surveyed the stresses and mechanisms for lyophilized protein and peptide products in 2020, and that survey remains a serviceable map. Which routes dominate for a given sequence depends on the residues present and on how the vial is treated between uses.
| Route | What drives it | Susceptible feature | Practical control |
|---|---|---|---|
| Backbone hydrolysis | Water activity, temperature, pH | Any amide bond, including those in the acyl linker | Keep the solid dry and sealed against desiccant |
| Deamidation | Water, temperature, pH above roughly 6 | Asparagine and glutamine side chains | Dry storage; cold |
| Oxidation | Headspace oxygen, light, trace metals | Methionine and tryptophan where present in the sequence | Dark storage, cold, minimal headspace |
| Aggregation and fibrillation | Interfaces, agitation, concentration, pH near the isoelectric point | Glucagon-family backbones and lipidated peptides | Dry, cold storage; avoid agitation |
| Surface adsorption | Contact with glass and some polymers | Amphiphilic peptides at low concentration | Container material chosen, fixed and documented |
Freezer temperature is not on that list as a mechanism. Cold slows every route above, which is why cold storage works, but temperature is a rate modifier. Moisture is the mechanism. A sealed vial held at room temperature and kept dry will often outlast one held at minus twenty and opened cold in a humid room every few days.
What survodutide storage conditions suit each physical state?
| State | Temperature | Light | Relative horizon | Why |
|---|---|---|---|---|
| Sealed powder, unopened stock | Minus 20 °C or below, desiccated | Dark | Longest | Water excluded and every route slowed |
| Sealed powder, in-use vial | 2 to 8 °C | Dark | Shorter than frozen | Adequate inside a defined working window |
| Powder in transit | Ambient, insulated | Dark | Days | Dry solids tolerate short excursions |
The horizons are relative on purpose. Assigning months to a specific lot needs stability data generated on that lot, in that closure, under those conditions. Where the certificate carries a retest or re-evaluation date, that date is the only one with any standing. Where it carries none, the honest entry in the record is that the window is unestablished.
What happens when a cold vial meets a warm room?
Take a vial from a minus twenty freezer into a laboratory at 22 °C and sixty percent relative humidity. The glass sits far below the dew point. Water condenses on every cold surface it can reach, and the moment the seal is broken that includes the inside of the vial and the cake itself, which is hygroscopic enough to take the water up immediately.
Nothing about this announces itself. A cake that has picked up a little moisture looks like a cake. The vial goes back to the freezer with water now inside, the next person opens it cold as well, and the loss compounds across a dozen unremarkable working sessions. In my experience this is the single largest avoidable degradation event in a peptide laboratory, and it never appears in a record because nobody knows it happened.
The control is dull, and it works the same way every time:
- Let the sealed vial reach room temperature before the seal is broken, with no exception for being in a hurry.
- Give a small vial twenty to thirty minutes on the bench. Touch the glass; if it is cool, it is not ready.
- Work quickly once open.
- Reseal against desiccant and return it promptly.
Drier is not automatically better in every system, incidentally. Work on lyophilizate formulations has found cases where raising residual moisture slightly improved stability, through water substituting for hydrogen bonds the excipient matrix could not supply. That is a formulation result, not a storage instruction, and it is a useful reminder that the intuitive rules here are approximations.
How do you confirm that storage held?
Storage claims are testable. The standard pairing is reversed-phase HPLC for purity and related substances, with UV detection in the 210 to 220 nm region where the peptide bond absorbs, plus LC-MS for identity against the expected monoisotopic or average mass. USP general chapters on chromatography and on the validation of compendial procedures set out what a defensible method looks like; a certificate that reports a purity figure without naming the method, the column chemistry and the gradient is reporting a number rather than a measurement.
Two practices make later comparison possible. First, keep the receipt chromatogram. A single reference injection run when the lot arrives gives every subsequent run a baseline, and a new shoulder at a slightly earlier retention time is far easier to spot against your own trace than against a supplier PDF. Second, note the total peak area, not only the purity percentage. Adsorptive loss and precipitation both reduce recovered material while leaving the relative purity looking fine.
Aggregation needs a different tool. Size-exclusion chromatography or a light-scattering method will detect soluble high-molecular-weight species that reversed-phase gradients can miss entirely, and for a glucagon-family sequence that is the failure mode I would most want visibility on. What documentation a competent supplier provides for identity and purity is set out under our quality standard.
What is the regulatory position?
Survodutide (BI 456906) is a dual glucagon receptor and GLP-1 receptor agonist under clinical development by Boehringer Ingelheim in collaboration with Zealand Pharma. It has been studied in phase 3 programs in obesity and in metabolic dysfunction-associated steatohepatitis, and the developer reported an FDA breakthrough therapy designation in MASH with fibrosis in 2024.
No regulator has authorized a survodutide product for marketing. There is therefore no approved formulation, no approved labeling, no assigned expiry and no lawful route to human use through any supply chain, research-grade or otherwise. Check ClinicalTrials.gov and the developer's own disclosures for current program status before repeating any status claim, including this one.
Status verified August 26, 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Handling for the closely related lipidated incretin analogs follows the same logic, and the longer worked treatment in the tirzepatide storage guide covers the condensation and freeze-thaw arguments in more depth.
Bottom line
Survodutide has no approved label, so no expiry from an incretin medicine carries over to a research vial. Keep the sealed powder cold, dark and dry, and let it warm before opening, because moisture is the main driver of loss.
Where the certificate carries a retest date, that is the only date with standing. Where it carries none, record the window as unestablished.
Common questions
What are the right survodutide storage conditions?
Does lyophilized survodutide have to be kept frozen?
Why can I not use the 28-day figure from approved incretin products?
Is aggregation a particular concern for this compound?
What should the record show for a vial that arrived warm?
Does light exposure matter for a dry powder?
More handling guides
Sources
- Zimmermann and colleagues, Molecular Metabolism, 2022. Preclinical characterization of BI 456906 as a glucagon receptor and GLP-1 receptor dual agonist; supports the mechanism and the description of the compound as an acylated peptide analogue.
- Butreddy et al., International Journal of Biological Macromolecules, 2020. Review of stresses, stabilization mechanisms and analytical techniques for lyophilized protein and peptide products; supports the degradation-route table and the primacy of dry solid-state storage.
- ICH Q1A(R2), Stability Testing of New Drug Substances and Products. Defines what generating a shelf life requires in terms of conditions, containers, lots and time points; supports the position that an unstudied research powder has no assignable expiry.
- USP General Chapters <621> Chromatography and <1225> Validation of Compendial Procedures. Establishes the method-reporting expectations that make an RP-HPLC purity figure interpretable on a certificate of analysis.
